Monthly information on share capital and company voting rights
November 08, 2022 16:30 ET
|
Cellectis Inc.
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
November 03, 2022 09:31 ET
|
Autolus Therapeutics plc
obe-cel: poster presentation in B-ALL and B-NHL patientsAUTO1/22: poster presentation in pediatric ALL patientsAUTO4: poster presentation in T-Cell Lymphoma patients LONDON, Nov. 03, 2022 ...
Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress
November 03, 2022 07:00 ET
|
Autolus Therapeutics plc
Pivotal FELIX Phase 2 clinical trial of obe-cel in relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (ALL) on track for Q4 2022 updateCommercial manufacturing site build on schedule for handover...
Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
October 21, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Moderna exercises option to license proprietary targeting technology from Autolus
October 12, 2022 07:00 ET
|
Autolus Therapeutics plc
- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna - - Autolus receives option exercise fee, with potential for development milestone payments plus...
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
October 04, 2022 07:00 ET
|
Autolus Therapeutics plc
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option...
mRNA Cancer Therapies Patent Landscape 2022: Featuring BioNTech, Moderna, Novartis, Sanofi & Others
October 04, 2022 04:03 ET
|
Research and Markets
Dublin, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering. For nearly three decades, extensive efforts...
Monthly information on share capital and company voting rights
September 19, 2022 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Global and China Passenger Car T-Box Market Report 2022-2025 Featuring 29 Major Chinese Vendors & 8 Major Global Vendors
September 05, 2022 07:38 ET
|
Research and Markets
Dublin, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The "Global and China Passenger Car T-Box Market Report, 2022" report has been added to ResearchAndMarkets.com's offering. Passenger car T-BOX research:...
Monthly information on share capital and company voting rights
August 22, 2022 16:30 ET
|
Cellectis Inc.
NEW YORK, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...